Can a patient with myasthenia gravis safely use benzonatate (Tessalon) for cough, and what is the appropriate dose?

Benzonatate (Tessalon) Use in Myasthenia Gravis

Benzonatate can be used cautiously in patients with myasthenia gravis for cough suppression, as it is a peripherally-acting antitussive that does not affect neuromuscular transmission, but close monitoring is essential and alternative cough suppressants should be considered first.

Key Safety Considerations

The critical distinction here is that benzonatate is NOT listed among the medications that worsen myasthenia gravis in the ASCO guidelines, which specifically warn against β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides 1, 2, 1, 2, 1. This is an important safety signal—benzonatate's absence from this list suggests it does not directly interfere with neuromuscular junction function.

Mechanism and Rationale

Benzonatate works by peripherally anesthetizing stretch receptors in the respiratory passages, lungs, and pleura, thereby reducing the cough reflex at its source 3. Critically, it has no inhibitory effect on the respiratory center in recommended dosages 3. This peripheral mechanism of action distinguishes it from centrally-acting opioid antitussives and theoretically makes it safer in myasthenia gravis patients who may already have compromised respiratory function.

Dosing Recommendations

Per FDA labeling 3:

• Standard dose: 100-200 mg three times daily as needed
• Maximum dose: 600 mg daily in three divided doses
• Critical instruction: Capsules must be swallowed whole—never broken, chewed, dissolved, cut, or crushed (risk of local anesthesia of oral mucosa and potential choking)
• Onset: 15-20 minutes
• Duration: 3-8 hours 3

Clinical Algorithm for Cough Management in MG Patients

Step 1: Assess Respiratory Status

• Perform pulmonary function testing with negative inspiratory force (NIF) and vital capacity (VC) 2
• Rule out myasthenic crisis or worsening disease as cause of cough
• Evaluate for concurrent myocarditis or myositis if on immune checkpoint inhibitors

Step 2: Consider Alternative Causes

• Evaluate for cough-variant asthma, GORD, or upper airway disease
• These may respond better to targeted therapy (inhaled corticosteroids, PPIs) 4

Step 3: Pharmacologic Hierarchy for MG Patients

1. First-line: Simple demulcents (glycerol-based linctus) 5
2. Second-line: Benzonatate 100-200 mg TID (peripheral action, no neuromuscular effects)
3. Third-line: Low-dose opioids (codeine 30 mg or morphine 5 mg) if benzonatate ineffective 5, 6
4. Last resort: Nebulized lidocaine 5 mL of 0.2% TID (assess aspiration risk first) 5

Critical Pitfalls to Avoid

Respiratory Monitoring

Patients with myasthenia gravis require frequent pulmonary function assessment when symptomatic 2. Any cough suppressant—including benzonatate—could theoretically mask worsening respiratory function. Monitor NIF and VC regularly.

Drug Interactions

While benzonatate itself doesn't worsen MG, ensure the patient is not on contraindicated medications:

• Avoid: β-blockers, fluoroquinolones, aminoglycosides, macrolides 1, 2
• Review: All current medications for potential neuromuscular effects

Capsule Integrity

The requirement to swallow capsules whole is non-negotiable 3. Patients with dysphagia (common in MG) may not be appropriate candidates for benzonatate—consider liquid formulations of alternative agents.

Evidence Quality Considerations

The evidence for benzonatate's efficacy is limited. A 2023 systematic review found that "existing evidence pertaining to the safety and clinical effectiveness of benzonatate" has "substantial limitations" with concerns for "high degrees of biases" 7. However, one RCT showed benzonatate combined with guaifenesin suppressed capsaicin-induced cough more effectively than either agent alone 8.

For lung cancer-related cough specifically, opioids (hydrocodone, dihydrocodeine) remain the best-studied suppressants 6, though benzonatate is mentioned as an option for opioid-resistant cough 5.

When to Escalate Care

If cough persists despite benzonatate or if any of the following develop:

• Worsening dysphagia, facial weakness, or limb weakness
• Declining NIF or VC
• Respiratory distress
• Signs of myasthenic crisis

Immediately consult neurology and consider admission for ICU-level monitoring 2.